Suppression of inter-ictal spikes by CM40907. A double-blind placebo-controlled investigation and review of spike counting as a methodology for assessing the antiepileptic effect of drugs.
To assess the efficacy of CM40907--a new antiepileptic drug--in suppressing inter-ictal spikes, 6 patients with severe intractable epilepsy and frequent spikes in their inter-ictal EEGs were entered in a double-blind placebo-controlled trial. The results show that CM40907 is efficacious in reducing spike counts in the first hour after oral administration. The results of the study are presented and inter-ictal spike counting as a method is discussed.
Yepez-Lasso
R
R
INSEG, Institute of Neurology, National Hospital, Queen Square, London, U.K.
Duncan
J S
JS
Shorvon
S D
SD
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D004311:Double-Blind Method; D004569:Electroencephalography; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011724:Pyridazines / Q000627:therapeutic use*
D000927:Anticonvulsants; D010919:Placebos; D011724:Pyridazines; C045387:CM 40907